Barrow, Hanley, Mewhinney & Strauss’s Pediatrix Medical MD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,032
Closed -$12K 337
2024
Q3
$12K Buy
1,032
+329
+47% +$3.1K ﹤0.01% 210
2024
Q2
$5.31K Hold
703
﹤0.01% 241
2024
Q1
$7.05K Hold
703
﹤0.01% 225
2023
Q4
$6.54K Sell
703
-344
-33% -$3.56K ﹤0.01% 219
2023
Q3
$13.3K Buy
1,047
+328
+46% +$4.5K ﹤0.01% 152
2023
Q2
$10.2K Buy
719
+157
+28% +$2.21K ﹤0.01% 182
2023
Q1
$8.38K Hold
562
﹤0.01% 194
2022
Q4
$8.35K Buy
562
+317
+129% +$5.17K ﹤0.01% 187
2022
Q3
$4K Sell
245
-20
-8% -$403 ﹤0.01% 226
2022
Q2
$6K Buy
265
+13
+5% +$265 ﹤0.01% 214
2022
Q1
$6K Sell
252
-2,855
-92% -$69.9K ﹤0.01% 227
2021
Q4
$85K Buy
3,107
+1,696
+120% +$45.4K ﹤0.01% 221
2021
Q3
$40K Hold
1,411
﹤0.01% 260
2021
Q2
$43K Buy
1,411
+587
+71% +$17.3K ﹤0.01% 258
2021
Q1
$21K Sell
824
-180
-18% -$4.61K ﹤0.01% 308
2020
Q4
$25K Sell
1,004
-1,647
-62% -$30.9K ﹤0.01% 296
2020
Q3
$43K Buy
+2,651
New +$49.3K ﹤0.01% 305

Other funds holding MD

Barrow, Hanley, Mewhinney & Strauss's MD Position: Q4 2024 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Pediatrix Medical (MD) in Q4 2024, closing a stake of 1,032 shares — an estimated $12K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in MD in Q3 2020 and held it in 17 quarters. The position peaked at $85K in Q4 2021. 229 funds tracked by Wall St. Rank hold MD as of Q4 2024.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Pediatrix Medical position as of Q4 2024 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 1,032 Pediatrix Medical shares in Q4 2024, an estimated $12K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Pediatrix Medical in Q3 2020 and held it in 17 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Pediatrix Medical position peaked at $85K in Q4 2021.
  • 229 funds tracked by Wall St. Rank held Pediatrix Medical as of Q4 2024.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q4 2024, filed 12 Feb 2025.